Critics have also pointed to the haste by which Sanofi’s Dengvaxia vaccine was exempted from the requirement that it be included in the National Drug Formulary before public funds are spent on it. We were projecting that once all of those steps done we can buy this (vaccine),” Aquino said. No one objectedAquino pointed out that before and after he approved the purchase of the vaccine, “no one” had advised him about any objection to the questionable dengue vaccine. He said that while the organization came out with a position paper on the dengue vaccine on July 2016, it did not make a “blanket” recommendation to use Dengvaxia. He also noted that the position paper came out after the dengue immunization program was launched by the Department of Health in April of the same year.

Source: Manila Times December 14, 2017 16:41 UTC